as 06-06-2025 4:00pm EST
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
Founded: | 2008 | Country: | Denmark |
Employees: | N/A | City: | N/A |
Market Cap: | 10.8M | IPO Year: | 2021 |
Target Price: | $10.00 | AVG Volume (30 days): | 134.8K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -6.01 | EPS Growth: | N/A |
52 Week Low/High: | $1.20 - $19.95 | Next Earning Date: | 05-27-2025 |
Revenue: | $3,293,000 | Revenue Growth: | 2555.64% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
EVAX Breaking Stock News: Dive into EVAX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Zacks Small Cap Research
4 days ago
GuruFocus.com
10 days ago
GlobeNewswire
11 days ago
Zacks Small Cap Research
11 days ago
GlobeNewswire
15 days ago
MT Newswires
16 days ago
GlobeNewswire
16 days ago
The information presented on this page, "EVAX Evaxion Biotech - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.